Myriad Genetics (MYGN) Stock Price

Myriad Genetics Price

NASDAQ·CLOSED
3.18USD+0.04 (+1.27 %)
Market closed

Revenue has compounded at 11.0% per year over the past 19 years to 824.50 M USD. Earnings per share have declined at 17.1% per year over the last 11 years. Myriad Genetics's net margin stands at -44.4%, down from -3.9% several years earlier. Analysts set a median price target of 7.14 USD, implying 124.5% above the current price. Of 18 analysts, 3 rate the stock a buy — an overall Hold consensus. The stock trades about 68% above its 52-week low.

Myriad Genetics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Myriad Genetics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Myriad Genetics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Myriad Genetics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Myriad Genetics Stock Price History
DateMyriad Genetics Price
8/6/20263.18 USD
8/5/20263.14 USD
8/4/20263.15 USD
8/3/20263.02 USD
7/31/20262.86 USD
7/30/20262.86 USD
7/29/20262.76 USD
7/27/20263.01 USD
7/23/20263.04 USD
7/22/20263.01 USD
7/21/20263.15 USD
7/20/20263.15 USD
7/17/20263.29 USD
7/16/20263.30 USD
7/15/20263.36 USD
7/14/20263.22 USD
7/13/20263.18 USD
7/10/20263.10 USD
7/9/20263.25 USD
7/8/20263.05 USD
7/7/20263.12 USD
7/6/20263.12 USD
7/2/20263.19 USD
7/1/20263.20 USD
6/30/20263.04 USD
6/29/20263.12 USD
6/26/20263.13 USD
6/25/20262.89 USD
6/24/20262.78 USD
6/23/20262.47 USD
6/22/20262.38 USD
6/18/20262.39 USD
6/17/20262.35 USD
6/16/20262.33 USD
6/15/20262.30 USD
6/12/20262.34 USD
6/11/20262.38 USD
6/10/20262.52 USD
6/9/20262.42 USD
6/8/20262.34 USD
6/5/20262.43 USD
6/4/20262.50 USD
6/3/20262.34 USD
6/2/20262.30 USD
6/1/20262.28 USD
5/29/20262.11 USD
5/28/20262.25 USD
5/27/20262.09 USD
5/26/20262.05 USD
5/22/20262.03 USD
5/21/20262.08 USD
5/20/20262.03 USD
5/19/20261.89 USD
5/18/20261.94 USD
5/15/20261.91 USD
5/14/20261.93 USD
5/13/20261.99 USD
5/12/20262.17 USD
5/11/20262.24 USD
5/8/20262.28 USD
5/7/20262.18 USD
5/6/20262.19 USD
5/5/20262.68 USD
5/4/20262.63 USD
5/1/20262.56 USD
4/30/20262.53 USD
4/29/20262.49 USD
4/28/20262.58 USD
4/27/20262.57 USD
4/24/20262.55 USD
4/23/20262.56 USD
4/22/20262.71 USD
4/21/20262.66 USD
4/20/20262.74 USD
4/17/20262.71 USD
4/16/20262.66 USD
4/15/20262.76 USD
4/14/20262.62 USD
4/13/20262.44 USD
4/10/20262.32 USD
4/9/20262.36 USD
4/8/20262.54 USD
4/7/20262.52 USD
4/6/20262.49 USD
4/2/20262.53 USD
4/1/20262.44 USD
3/31/20262.40 USD
3/30/20262.32 USD
3/27/20262.28 USD
3/26/20262.46 USD
3/25/20262.49 USD
3/24/20262.46 USD
3/23/20262.48 USD
3/20/20262.44 USD
3/19/20262.53 USD
3/18/20262.47 USD
3/17/20262.55 USD
3/16/20262.44 USD
3/13/20262.48 USD
3/12/20262.58 USD
3/11/20262.69 USD
3/10/20262.73 USD
3/9/20262.56 USD
3/6/20262.74 USD
3/5/20262.73 USD
3/4/20262.81 USD
3/3/20262.82 USD
3/2/20262.67 USD
2/27/20262.46 USD
2/26/20262.59 USD
2/25/20262.55 USD
2/24/20262.36 USD
2/23/20262.33 USD
2/20/20262.28 USD
2/19/20262.33 USD
2/18/20262.33 USD
2/17/20262.40 USD
2/13/20262.39 USD
2/12/20262.41 USD
2/11/20262.58 USD
2/10/20262.71 USD
2/9/20262.70 USD
2/6/20262.73 USD
2/5/20262.72 USD
2/4/20262.82 USD
2/3/20262.84 USD
2/2/20262.91 USD
1/30/20262.99 USD
1/29/20262.95 USD
1/28/20263.05 USD
1/27/20263.15 USD
1/26/20263.09 USD
1/23/20263.13 USD
1/22/20263.23 USD
1/21/20263.11 USD
1/20/20263.03 USD
1/16/20263.15 USD
1/15/20263.22 USD
1/14/20263.25 USD
1/13/20263.30 USD
1/12/20263.50 USD
1/9/20263.50 USD
1/8/20263.49 USD
1/7/20263.53 USD
1/6/20263.47 USD
1/5/20263.27 USD
1/2/20263.27 USD
12/31/20253.28 USD
12/30/20253.29 USD
12/29/20253.36 USD
12/26/20253.45 USD
12/24/20253.49 USD
12/23/20253.49 USD
12/22/20253.60 USD
12/19/20253.49 USD
12/18/20253.57 USD
12/17/20253.70 USD
12/16/20253.66 USD
12/15/20253.72 USD
12/12/20253.84 USD
12/11/20253.89 USD
12/10/20253.85 USD
12/9/20253.91 USD
12/8/20253.77 USD
12/5/20253.78 USD
12/4/20253.90 USD
12/3/20253.90 USD
12/2/20253.74 USD
12/1/20253.76 USD
11/28/20254.06 USD
11/26/20254.05 USD
11/25/20254.21 USD
11/24/20254.12 USD
11/21/20253.93 USD
11/20/20253.67 USD
11/19/20253.43 USD
11/18/20253.53 USD
11/17/20253.55 USD
11/14/20253.57 USD
11/13/20253.38 USD
11/12/20253.48 USD
11/11/20253.56 USD
11/10/20253.45 USD
11/7/20253.36 USD
11/6/20253.37 USD
11/5/20253.50 USD
11/4/20253.44 USD
11/3/20254.36 USD
10/31/20254.28 USD
10/30/20254.23 USD
10/29/20254.21 USD
10/28/20254.33 USD
10/27/20254.31 USD
10/24/20254.34 USD
10/23/20254.29 USD
10/22/20254.19 USD
10/21/20254.29 USD
10/20/20254.21 USD
10/17/20254.15 USD
10/16/20254.30 USD
10/15/20254.31 USD
10/14/20254.15 USD
10/13/20254.18 USD
10/10/20253.99 USD
10/9/20254.12 USD
10/8/20254.07 USD
10/7/20254.01 USD
10/6/20254.26 USD
10/3/20254.29 USD
10/2/20254.03 USD
10/1/20254.12 USD
9/30/20253.85 USD
9/29/20253.85 USD
9/26/20254.10 USD
9/25/20254.13 USD
9/24/20254.11 USD
9/23/20254.10 USD
9/22/20254.18 USD
9/19/20254.14 USD
9/18/20254.09 USD
9/17/20253.94 USD
9/16/20253.99 USD
9/15/20253.89 USD
9/12/20253.86 USD
9/11/20254.09 USD
9/10/20253.67 USD
9/9/20253.71 USD
9/8/20253.68 USD
9/5/20253.52 USD
9/4/20253.62 USD
9/3/20253.62 USD
9/2/20253.67 USD
8/29/20253.39 USD
8/28/20253.31 USD
8/27/20253.16 USD
8/26/20253.09 USD
8/25/20253.14 USD
8/22/20253.21 USD
8/21/20253.10 USD
8/20/20252.95 USD
8/19/20252.93 USD
8/18/20253.04 USD
8/15/20253.04 USD
8/14/20253.14 USD
8/13/20253.13 USD
8/12/20253.21 USD
8/11/20253.30 USD
Access this data via the Eulerpool API
Get Free API Key

Myriad Genetics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
753.20 M USD
-259.30 M USD
-263.30 M USD
Jan 1, 2024
837.60 M USD
-122.40 M USD
-127.30 M USD
Jan 1, 2025
824.50 M USD
-67.80 M USD
-365.90 M USD
Jan 1, 2026 (e)
863.56 M USD
-212.52 M USD
5.67 M USD
Jan 1, 2027 (e)
915.77 M USD
-225.37 M USD
13.99 M USD
Jan 1, 2028 (e)
970.10 M USD
-238.74 M USD
25.16 M USD
Jan 1, 2029 (e)
1.08 B USD
-264.65 M USD
52.78 M USD
Jan 1, 2030 (e)
1.10 B USD
-269.75 M USD
59.26 M USD

Myriad Genetics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 9, 2026, 8:31 AM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
0.720.750.770.770.850.560.690.680.750.840.820.860.920.971.081.10
-7.074.152.390.1310.23-34.5523.88-1.7411.0611.16-1.554.736.036.0110.821.95
79.5379.1577.8277.0776.3867.8671.4570.2168.6669.8969.9069.9069.9069.9069.9069.90
575.00596.00600.00595.00650.00378.00493.00476.00517.00585.00576.00603.26639.61678.06751.46766.14
134.00166.0049.00118.0023.00-194.00-51.00-140.00-259.00-122.00-67.00-212.00-225.00-238.00-264.00-269.00
18.5322.056.3615.282.70-34.83-7.39-20.65-34.40-14.58-8.13-24.57-24.59-24.54-24.56-24.54
80.00125.0021.00131.004.00-223.00-27.00-112.00-263.00-127.00-365.005.0013.0025.0052.0059.00
-54.5556.25-83.20523.81-96.95-5,675.00-87.89314.81134.82-51.71187.40-101.37160.0092.31108.0013.46
73.8068.3071.9076.5074.4075.3079.9081.5086.1091.1093.3093.3093.3093.3093.3093.30
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Myriad Genetics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Myriad Genetics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Myriad Genetics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Myriad Genetics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Myriad Genetics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Myriad Genetics stock margins

The Myriad Genetics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Myriad Genetics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Myriad Genetics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
71.39 %
-7.41 %
-3.94 %
Jan 1, 2022
70.22 %
-20.64 %
-16.51 %
Jan 1, 2023
68.64 %
-34.43 %
-34.96 %
Jan 1, 2024
69.89 %
-14.61 %
-15.20 %
Jan 1, 2025
69.93 %
-8.22 %
-44.38 %
Jan 1, 2026 (e)
69.93 %
-24.61 %
0.66 %
Jan 1, 2027 (e)
69.93 %
-24.61 %
1.53 %
Jan 1, 2028 (e)
69.93 %
-24.61 %
2.59 %

Myriad Genetics Stock Revenue, EBIT, Earnings per Share

The Myriad Genetics earnings per share therefore indicates how much revenue Myriad Genetics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
8.64 USD
-0.64 USD
-0.34 USD
Jan 1, 2022
8.32 USD
-1.72 USD
-1.37 USD
Jan 1, 2023
8.75 USD
-3.01 USD
-3.06 USD
Jan 1, 2024
9.19 USD
-1.34 USD
-1.40 USD
Jan 1, 2025
8.84 USD
-0.73 USD
-3.92 USD
Jan 1, 2026 (e)
9.33 USD
-2.28 USD
0.06 USD
Jan 1, 2027 (e)
9.89 USD
-2.42 USD
0.15 USD
Jan 1, 2028 (e)
10.48 USD
-2.56 USD
0.27 USD

Myriad Genetics business model & stock analysis

Myriad Genetics Inc. is a biotechnology company specializing in the research of cancer and genetic analysis technologies. The company was founded in 1991 by Mark Skolnick and has since become a global leader in personalized medicine and diagnostics. It is headquartered in Salt Lake City, Utah, USA, and employs over 2,400 employees worldwide.

Myriad Genetics SWOT Analysis

Strengths

1. Strong Intellectual Property Portfolio: Myriad Genetics Inc possesses a significant number of patents and licenses, providing a competitive advantage in the genetic testing industry.

2. Broad Range of Products and Services: The company offers a comprehensive suite of genetic tests and related services, catering to different medical specialties and patient needs.

3. Established Market Presence: Myriad Genetics Inc has achieved a reputable position in the market, with a long history of delivering reliable genetic testing solutions and gaining the trust of healthcare professionals.

Weaknesses

1. Dependence on Few Key Products: Myriad Genetics Inc relies heavily on a limited number of flagship products, which exposes the company to the risk of market fluctuations and potential loss of market share.

2. Regulatory Challenges: The genetic testing industry is tightly regulated, and changing regulations can impact Myriad Genetics Inc's ability to operate or require costly compliance measures.

3. Limited International Expansion: The company's presence is primarily concentrated in the United States, limiting its potential growth opportunities in international markets.

Opportunities

1. Growing Demand for Genetic Testing: The increasing awareness and importance of personalized medicine present a significant opportunity for Myriad Genetics Inc to expand its customer base and introduce new testing solutions.

2. Advances in Genetic Research: Technological advancements and ongoing research in genetics offer the potential for the development of innovative tests and services, allowing the company to stay ahead of competitors.

3. Strategic Partnerships: Collaborating with pharmaceutical companies, healthcare organizations, and research institutions can provide Myriad Genetics Inc with access to new markets, resources, and expertise.

Threats

1. Competition: The genetic testing industry is becoming increasingly competitive, with the entry of new players and the presence of established companies offering similar services, posing a threat to Myriad Genetics Inc's market share.

2. Reimbursement Challenges: Changes in healthcare policies and reimbursement rates can impact the company's profitability and restrict patient access to genetic testing services.

3. Ethical and Legal Concerns: The handling and interpretation of genetic data raise ethical and privacy concerns, requiring Myriad Genetics Inc to continually address legal and regulatory challenges.

Myriad Genetics Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Myriad Genetics Employees
Details
Date
Myriad Genetics Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Myriad Genetics Segments

Myriad Genetics Revenue by Segment (1/5)

  • 3 Years

  • 5 Years

  • Max

Molecular diagnostic testing
Molecular diagnostic hereditary cancer testing
Molecular diagnostic GeneSight testing
Molecular diagnostic Prenatal testing
Pharmaceutical and clinical services
Molecular diagnostic Vectra testing
Molecular diagnostic Prolaris testing
Molecular diagnostic other testing
Molecular diagnostic EndoPredict testing
Details
Date
Testing Revenue
Molecular diagnostic testing
Molecular diagnostic revenues
Molecular diagnostic hereditary cancer testing
Hereditary Cancer
Prenatal
Pharmacogenomics
Mental Health
Tumor Profiling
Molecular diagnostic GeneSight testing
Molecular diagnostic Prenatal testing
Pharmaceutical and clinical services
Molecular diagnostic Vectra testing
Molecular diagnostic Prolaris testing
Molecular diagnostic other testing
Molecular diagnostic EndoPredict testing
Other revenue
Autoimmune
Jan 1, 2013
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2014
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2015
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2016
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2018
0.00 USD
719.30 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
53.30 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
479.70 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
112.60 M USD
104.90 M USD
0.00 USD
48.30 M USD
25.50 M USD
8.00 M USD
10.40 M USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Myriad Genetics Revenue by Segment (2/5)

  • 3 Years

  • 5 Years

  • Max

Molecular diagnostic testing
Pharmaceutical and clinical services
Details
Date
Molecular diagnostic testing
Pharmaceutical and clinical services
Jan 1, 2013
0.00 USD
0.00 USD
Jan 1, 2014
0.00 USD
0.00 USD
Jan 1, 2015
0.00 USD
0.00 USD
Jan 1, 2016
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
0.00 USD
Jan 1, 2018
0.00 USD
0.00 USD
Jan 1, 2019
789.40 M USD
61.70 M USD
Jan 1, 2020
586.90 M USD
51.70 M USD

Myriad Genetics Revenue by Segment (3/5)

  • 3 Years

  • 5 Years

  • Max

Molecular diagnostic hereditary cancer testing
Molecular diagnostic GeneSight testing
Molecular diagnostic Prenatal testing
Molecular diagnostic Vectra testing
Molecular diagnostic Prolaris testing
Molecular diagnostic other testing
Molecular diagnostic EndoPredict testing
Details
Date
Molecular diagnostic hereditary cancer testing
Molecular diagnostic GeneSight testing
Molecular diagnostic Prenatal testing
Molecular diagnostic Vectra testing
Molecular diagnostic Prolaris testing
Molecular diagnostic other testing
Molecular diagnostic EndoPredict testing
Jan 1, 2013
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2014
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2015
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2016
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
347.40 M USD
74.10 M USD
76.70 M USD
39.10 M USD
24.70 M USD
14.40 M USD
10.50 M USD

Myriad Genetics Revenue by Segment (4/5)

  • 3 Years

  • 5 Years

  • Max

Other
Details
Date
Other
Jan 1, 2013
0.00 USD
Jan 1, 2014
0.00 USD
Jan 1, 2015
0.00 USD
Jan 1, 2016
0.00 USD
Jan 1, 2017
0.00 USD
Jan 1, 2018
0.00 USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
45.10 M USD

Myriad Genetics Revenue by Segment (5/5)

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Molecular Diagnostics
Diagnostics
Other
Other Segments
Companion Diagnostics
Pharmaceutical And Clinical Services
Details
Date
Molecular Diagnostics
Diagnostics
Other
Other Segments
Companion Diagnostics
Pharmaceutical And Clinical Services
Jan 1, 2013
582.39 M USD
0.00 USD
0.00 USD
0.00 USD
30.77 M USD
0.00 USD
Jan 1, 2014
748.20 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
30.02 M USD
Jan 1, 2015
0.00 USD
695.50 M USD
0.00 USD
27.60 M USD
0.00 USD
0.00 USD
Jan 1, 2016
0.00 USD
705.70 M USD
0.00 USD
48.10 M USD
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
722.10 M USD
49.30 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2018
0.00 USD
719.30 M USD
53.30 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
789.40 M USD
61.70 M USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
593.50 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Myriad Genetics Revenue by Region

  • 3 Years

  • Max

United States
International
RoW
Details
Date
United States
International
RoW
Jan 1, 2021
603.70 M USD
86.90 M USD
0.00 USD
Jan 1, 2022
591.50 M USD
86.90 M USD
0.00 USD
Jan 1, 2023
671.70 M USD
81.50 M USD
0.00 USD
Jan 1, 2024
769.50 M USD
68.10 M USD
0.00 USD
Jan 1, 2025
768.00 M USD
0.00 USD
56.50 M USD

Myriad Genetics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Myriad Genetics historical P/E ratio, EBIT multiple, and P/S ratio

Myriad Genetics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Myriad Genetics shares outstanding

The number of shares of Myriad Genetics was 93.3 M in 2025. This indicates how many shares Myriad Genetics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
79.90 M Stocks
Jan 1, 2022
81.50 M Stocks
Jan 1, 2023
86.10 M Stocks
Jan 1, 2024
91.10 M Stocks
Jan 1, 2025
93.30 M Stocks
Jan 1, 2026 (e)
93.30 M Stocks
Jan 1, 2027 (e)
93.30 M Stocks
Jan 1, 2028 (e)
93.30 M Stocks

Myriad Genetics stock splits

In Myriad Genetics's history, there have been no stock splits.

Current Myriad Genetics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
16.67 % (3)
Hold
50.00 % (9)
Sell
33.33 % (6)
12M Price Target
7.14
Last Price
3.26
Currency
USD
12M Return Potential
119.02 %
LTM Return
0 %

Myriad Genetics Analyst Rating Actions

DateFirmActionRatingReliability
7/31/2026
TD Cowen
TD Cowen
MaintainedHold60
5/6/2026
Wells Fargo
Wells Fargo
MaintainedEqual Weight56
5/6/2026
TD Cowen
TD Cowen
MaintainedHold60
2/24/2026
Wells Fargo
Wells Fargo
MaintainedEqual Weight56
2/24/2026
UBS
UBS
MaintainedNeutral51
11/11/2025
Piper Sandler
Piper Sandler
MaintainedOverweight51
11/5/2025
Wells Fargo
Wells Fargo
MaintainedEqual Weight56
11/4/2025
UBS
UBS
MaintainedNeutral51
11/4/2025
TD Cowen
TD Cowen
MaintainedHold60
5/21/2025
Scotiabank
Scotiabank
DowngradeSector OutperformSector Perform75

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Myriad Genetics Earnings Calls

2025

Myriad Genetics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
7/30/2026-0.06USD-210.15 MUSD-2026 Q2
5/4/2026-0.07USD-206.43 MUSD-2026 Q1
3/3/2026-0.02USD-211.13 MUSD-2025 Q4
5/1/2024-0.03USD-199.38 MUSD-2024 Q1
2/26/20240.02USD-197.99 MUSD-2023 Q4
11/15/2022-0.06USD-178.38 MUSD-2023 Q3
11/1/2022-0.06USD-172.65 MUSD-2022 Q3
8/4/20220.01USD-173.57 MUSD-2022 Q2
5/5/2022-0.07USD-158.97 MUSD-2022 Q1
2/24/2022-0.02USD-165.85 MUSD-2021 Q4

EESG©

Eulerpool ESG Scorecard© for the Myriad Genetics stock

41/100
36
Environment
51
Social
37
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees61
Percentage of women in management—
Percentage of Asian employees8
Share of Asian management—
Percentage of Hispanic/Latino employees7
Hispano/Latino Management share—
Percentage of Black employees4
Black Management Share—
Percentage of white employees77
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Myriad Genetics shareholder structure

% Name
14.75276%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
8.76610%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
7.23559%
Millennium Management LLC
Millennium Management LLC
6.44338%
State Street Investment Management (US)
State Street Investment Management (US)
5.33592%
Glenview Capital Management, LLC
Glenview Capital Management, LLC
4.86522%
D. E. Shaw & Co., L.P.
D. E. Shaw & Co., L.P.
...

Myriad Genetics Beneficial Ownership Filings (SEC 13D/G)

Free Float
93.0%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
18.40%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
11.46%
The Vanguard Group - 23-1945930
The Vanguard Group - 23-1945930
SEC ↗
11.00%
Baillie Gifford & Co (Scottish partnership)
Baillie Gifford & Co (Scottish partnership)
SEC ↗
8.50%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
6.30%
Capital Research Global Investors **
Capital Research Global Investors **
SEC ↗
5.70%
Southeastern Asset Management, Inc.
Southeastern Asset Management, Inc.
SEC ↗
5.60%
Integrated Core Strategies (US) LLC
Integrated Core Strategies (US) LLC
SEC ↗
5.31%
LARRY ROBBINS
LARRY ROBBINS
SEC ↗
5.30%
GLENVIEW CAPITAL MANAGEMENT, LLC
GLENVIEW CAPITAL MANAGEMENT, LLC
SEC ↗
5.28%
Sterling Capital Management LLC
Sterling Capital Management LLC
SEC ↗

Myriad Genetics Executives and Management Board

18 members · avg. age 56 · 33 % women

SR

Mr. Samraat Raha (52)

President, Chief Executive Officer, Director · since 2023

4.39 M USD

Management

MV

Mr. Mark Verratti (56)

Chief Operating Officer and Chief Commercial Officer

3.71 M USD
DM

Dr. Dale Muzzey (45)

Chief Scientific Officer

3.01 M USD
KH

Mr. Kevin Haas (40)

Chief Technology Officer

1.64 M USD
BW

Mr. Benjamin Wheeler (42)

Chief Financial Officer

–
SS

Ms. Shereen Solaiman (52)

Chief People Officer

–
MA

Ms. Margaret Ancona (55)

Senior Vice President, Chief of Staff

–

Board of Directors

SP

Ms. S. Louise Phanstiel (66)

Independent Chairman of the Board

563,499.00 USD
PB

Mr. Paul Bisaro (64)

Independent Director

449,345.00 USD
LN

Dr. Lee Newcomer (73)

Independent Director

447,999.00 USD
HD

Dr. Heiner Dreismann (71)

Independent Director

443,499.00 USD
CR

Ms. Colleen Reitan (65)

Independent Director

443,499.00 USD
RK

Ms. Rashmi Kumar (55)

Independent Director

433,499.00 USD

Myriad Genetics Supply Chain

Myriad Genetics Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
16 companies
#NameTrend
1
Progyny
Customer·Health Care Providers & Services·US
0.86
0.43
0.85
0.56
0.75
0.89
2
Abbott Laboratories
Supplier·Customer·Health Care Equipment & Supplies·US
0.26
0.60
0.61
0.72
0.16
0.73
3
Illumina
Supplier·Customer·Life Sciences Tools & Services·US
0.44
0.23
0.71
0.78
0.89
0.68
4
Johnson & Johnson
Supplier·Customer·Pharmaceuticals·US
0.10
-0.34
-0.76
-0.68
-0.29
0.68
5
Eli Lilly
Supplier·Customer·Pharmaceuticals·US
0.20
0.59
-0.24
-0.54
-0.57
0.61
#NameTrend
1
Luminex Corporation
Supplier·US
-0.08
0.10
-0.42
-0.63
-0.82
—
2
GlaxoSmithKline
Supplier·Customer·Pharmaceuticals·GB
0.51
0.36
-0.69
-0.64
-0.83
-0.25
3
Merck & Co
Supplier·Customer·Pharmaceuticals·US
0.03
0.50
-0.69
-0.72
-0.50
-0.15
4
AstraZeneca
Supplier·Customer·Pharmaceuticals·GB
0.48
0.45
-0.56
-0.74
-0.61
-0.12
5
Sanofi
Supplier·Customer·Pharmaceuticals·FR
-0.17
0.35
-0.61
-0.70
-0.74
-0.07

Frequently asked questions about Myriad Genetics

The business model of Myriad Genetics Inc revolves around providing molecular diagnostic tests and genetic analysis services. As a leading molecular diagnostics company, Myriad Genetics focuses on developing and marketing innovative genetic tests for various medical conditions, including cancer and genetic disorders. With a strong emphasis on research and technology, Myriad Genetics aims to improve patient care and outcomes through personalized medicine. By offering a wide range of genetic testing services, the company strives to empower healthcare providers and individuals with valuable genetic insights, enabling more precise diagnosis, treatment decisions, and proactive healthcare management. Myriad Genetics Inc's business model primarily centers on genetic testing for various medical conditions.

Myriad Genetics Inc is primarily active in the healthcare and biotechnology industries.

The main competitors of Myriad Genetics Inc in the market include companies like Invitae Corporation, Illumina Inc, NeoGenomics Laboratories Inc, and Natera Inc.

Myriad Genetics Inc is a leading molecular diagnostics company based in the United States. Founded in 1991, the company has a rich history and has made significant contributions to the field of genetic testing and personalized medicine. Myriad Genetics Inc specializes in developing and marketing innovative genetic tests, including those for hereditary cancer and rare diseases. With a strong focus on research and development, the company has established itself as a trusted provider of genetic testing services worldwide. Myriad Genetics Inc's commitment to advancing healthcare through genetic insights has made it a prominent player in the industry.

Myriad Genetics Inc has achieved several significant milestones throughout its history. One notable achievement is the development of the BRACAnalysis test, which is a groundbreaking genetic test used to identify individuals with a higher risk of developing hereditary breast and ovarian cancer. This test has revolutionized the field of genetic testing and has had a major impact on cancer prevention and treatment. Additionally, Myriad Genetics Inc has successfully expanded its portfolio to include various genetic tests for other diseases, including prostate cancer and hereditary colon cancer. The company continues to innovate and make strides in the field of genetic testing, solidifying its position as a leader in the industry.

Myriad Genetics Inc is primarily present in various countries and regions worldwide. The company has a global presence, with operations and offices in several key locations. Some of the countries and regions where Myriad Genetics Inc is primarily present include the United States, Canada, Europe (including countries like the United Kingdom, France, Germany, Italy, and Spain), Asia Pacific (including countries like Japan, China, and Australia), and Latin America. This widespread presence allows Myriad Genetics Inc to serve a wide range of customers and collaborate with medical professionals and researchers globally.

Myriad Genetics Inc represents values of innovation, dedication to patients, and commitment to improving healthcare through genetic testing and personalized medicine. With a corporate philosophy centered around advancing precision medicine, Myriad Genetics is focused on developing groundbreaking molecular diagnostic tests that enable early detection and prevention of diseases such as cancer. The company aims to empower healthcare professionals and patients with reliable, actionable genetic information to make informed decisions about treatment and preventative measures. Myriad Genetics' dedication to quality, accuracy, and ethical practices makes it a trusted leader in the field of genetic testing and precision medicine.

Analysts currently set an average price target of 7.85 USD for the Myriad Genetics stock (median: 7.14 USD), implying +140.9 % versus the latest price. The consensus is based on 18 analyst ratings.

Myriad Genetics Analyst Price Targets 2026

18 analysts currently rate the Myriad Genetics stock: 3 recommend buying, 9 holding and 6 selling. For 2026, analysts expect Myriad Genetics to generate revenue of 863.56 M USD and earnings per share of 0.06 USD.

Myriad Genetics Analyst Price Targets 2026

Converted at the current exchange rate, the Myriad Genetics share trades at 2.75 EUR (3.18 USD).

The Myriad Genetics share (MYGN) is listed on 9 stock exchanges, including: NASDAQ (MYGN), XETRA (MYD.DE), Frankfurt (MYD.F), München (MYD.MU), Düsseldorf (MYD.DU), Hamburg (MYD.HM), London (0K3W.L), London (0K3W.L).

The company Myriad Genetics Inc. is a US-American company that specializes in the development and marketing of medical testing procedures and personalized medicine solutions. The business model includes three main divisions: genetic testing, molecular diagnostics, and personalized medicine. In the genetic testing division, Myriad Genetics offers a comprehensive range of genetic tests, including BRCA1 and BRCA2 tests, which are specifically designed to identify the risk of breast cancer in women and men. In addition, the company offers tests for hereditary colon and skin cancer, as well as tests for genetic disorders and hereditary types of cancer. These tests are aimed at providing doctors with a solid basis for making informed decisions, diagnosing accurately, and choosing the best treatment options for their patients. In molecular diagnostics, the company focuses on developing testing procedures specifically designed to identify the genetic basis of certain diseases. Myriad Genetics has developed a wide range of molecular tests that are used in the early detection and treatment of diseases such as breast cancer, colon cancer, and prostate cancer. Personalized medicine reflects the core idea of Myriad Genetics' business model. It involves using a patient's genetics to develop individualized treatment options. The company has developed various technologies tailored to an individual's genetic profile to enable better prediction of the effectiveness of medications and therapies. The goal is to create tailored, targeted treatment methods for patients through personalized medicine and genomic therapies. An important part of Myriad Genetics' business is collaboration with leading researchers, doctors, and medical institutions worldwide. The company has established partnerships with leading oncologists and cancer centers to promote the use of tests and personalized medicine solutions. Additionally, Myriad Genetics has a strong research department that continuously focuses on new technologies and innovative therapies for the treatment of cancer and other serious illnesses. Overall, Myriad Genetics' business model offers a comprehensive range of innovative products and services for the medical community and patients worldwide. The company continuously works to expand and improve its offerings in order to provide the best possible diagnosis and treatment options based on the individual genetic characteristics of each patient.

The expected revenue of Myriad Genetics is 863.56 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Myriad Genetics is 5.67 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Myriad Genetics is currently 52.31. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Myriad Genetics stock.

The price-to-sales ratio (P/S) of Myriad Genetics is currently 0.34. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Myriad Genetics stock.

The Eulerpool Quality Score for Myriad Genetics is 2/10.

The ISIN of Myriad Genetics is US62855J1043. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Myriad Genetics is 897518. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Myriad Genetics is MYGN. The ticker symbol is used to trade Myriad Genetics shares on the stock exchange.

Myriad Genetics paid dividends every year for the past 0 years.

Myriad Genetics is assigned to the 'Health' sector.

The dividends of Myriad Genetics are distributed in USD.

All fundamentals and in-depth analysis of Myriad Genetics

Our stock analysis for Myriad Genetics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Myriad Genetics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Myriad Genetics Stock
Myriad Genetics Revenue→
Myriad Genetics Stock
Myriad Genetics Net Income→
Myriad Genetics Stock
Myriad Genetics P/E→
Myriad Genetics Stock
Myriad Genetics P/S→
Myriad Genetics Stock
Myriad Genetics EBIT→
Myriad Genetics Stock
Myriad Genetics Dividend→
Myriad Genetics Stock
Myriad Genetics Directors Dealings→
Myriad Genetics Stock
Myriad Genetics Stocks→
Myriad Genetics Stock
Myriad Genetics Market capitalization→
Myriad Genetics Stock
Myriad Genetics Debt→
Myriad Genetics Stock
Myriad Genetics Liabilities→
Myriad Genetics Stock
Myriad Genetics Equity→
Myriad Genetics Stock
Myriad Genetics AAQS→
Myriad Genetics Stock
Myriad Genetics Employees→
Myriad Genetics Stock
Myriad Genetics ROE→
Myriad Genetics Stock
Myriad Genetics ROA→
Myriad Genetics Stock
Myriad Genetics ROCE→
Myriad Genetics Stock
Myriad Genetics News→
Myriad Genetics Stock
Myriad Genetics Analyst Price Targets→

Health Stocks

Myung In Pharm CoMyrexisMyungmoon Pharm CoMyomoN G IndustriesMynd.ai,Naba Alsaha Medical Services Company SJSCMycenax BiotechNabriva TherapeuticsMustang BioNagaileben CoMurni Sadar Tbk PTAll Stocks A–Z →